MedTrace Logo

Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer

NCT01105364 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-08-12

No results posted yet for this study

Summary

RATIONALE: Diagnostic procedures, such as contrast-enhanced ultrasound, may help measure a patient's response to treatment with drugs such as sunitinib malate, sorafenib tosylate, or bevacizumab, and allow doctors to plan better treatment.

PURPOSE: This clinical trial is studying ultrasonography in assessing antiangiogenic treatment in patients with advanced kidney cancer.

Conditions

Interventions

DRUG

antiangiogenesis therapy

DRUG

stabilized sulphur hexafluoride microbubble-based contrast agent

OTHER

imaging biomarker analysis

OTHER

pharmacological study

PROCEDURE

computed tomography

PROCEDURE

magnetic resonance imaging

Sponsors & Collaborators

  • National Cancer Institute, France

    lead OTHER_GOV

Principal Investigators

  • F. Bruyere, MD · Centre Hospitalier Universitaire Bretonneau de Tours

Study Design

Purpose
DIAGNOSTIC

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2012-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01105364 on ClinicalTrials.gov